09.05.20124-Antibody AG and Evotec AG form Strategic Collaboration

4-Antibody and Evotec launch a new high-content screening platform for early antibody functionality testing

Press Release

27.04.2012Jazz Pharmaceuticals to Acquire EUSA Pharma

Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
for $650 million in cash plus a potential $50 million milestone payment

Press Release


CN Creative, Ltd. (CNC), a healthcare company providing innovative and sustainable solutions to reduce smoking and smoking-related illnesses, today announced that Tim Byrne has been appointed Chief Financial Officer.

Press Release


Cellnovo today announced both the launch of the world’s only mobile-connected diabetes management system, and the start of the largest usability trial ever to investigate insulin pump technology for patients with type 1 diabetes.

Press Release

31.01.2012CN Creative - Intellicig Electronic Cigarettes on ITV show "This Morning"

Linda Robson's comment as she was handed an Intellicig to try on the 'This Morning' show on ITV said it all; "Fantastic!" she exclaimed.

In The News

26.01.2012Amgen to Acquire Micromet

Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies

Press Release

26.01.2012Celgene to Acquire Avila Therapeutics

Oral Btk inhibitor AVL-292 offers promising potential for treatment of B-cell diseases

Press Release

25.01.2012CN Creative Raises Series A Funding to Develop First Medically Approved Electronic Inhaler Nicotine Replacement Therapy for Smoking Cessation

CNC Combining Its Broad Expertise in Smoking Cessation and Electronic Cigarette Technology to Offer Smokers New Medical Options to Reduce Harm and Help Them Quit

Press Release

20.01.2012Advent Life Sciences Invests in Acutus Medical and Acutus Medical Expands Senior Management Team

Funds and team growth for developing a breakthrough medical system for mapping of atrial fibrillation

Press Release

20.01.2012Avila Announces FDA Allowance of Partner Clovis Oncology’s IND Application

Avila Announces FDA Allowance of Partner Clovis Oncology’s IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor - Triggers $4 Million Milestone Payment to Avila

Press Release